Trial Profile
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2019
Price :
$35
*
At a glance
- Drugs Eleclazine (Primary)
- Indications Ventricular arrhythmias
- Focus Therapeutic Use
- Acronyms TEMPO
- Sponsors Gilead Sciences
- 15 Nov 2017 Primary endpoint (Overall occurrence (total number) of appropriate ICD interventions (ATP or shock) through Week 24) has not been met as per the results presented at the 90th Annual Scientific Sessions of the American Heart Association
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
- 03 Nov 2016 Status changed from active, no longer recruiting to completed.